Ardelyx, Inc. (ARDX): who owns it and who trades it
As of Nov 16, 2026, ARDX insiders reported 74 open-market sales worth $4.3M and 1 purchase worth $1.9M in the last 12 months, with 48% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael Raab (CEO), with $2.6M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ardelyx
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ARDX
248 funds and institutions reported ARDX shares worth $916M at the end of Q2 2026, about 73% of the company. The largest holder is BlackRock, Inc. with 9.5%.
Funds and institutions (13F) 73%Everyone else 27%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 23.50M | 9.51% | $120M | +11% |
| Rubric Capital Management LP | 16.20M | 6.56% | $82.6M | +771% |
| Millennium Management LLC | 13.90M | 5.63% | $70.9M | -22% |
| State Street Corp | 13.36M | 5.41% | $68.1M | -2% |
| Vanguard Capital Management LLC | 10.47M | 4.24% | $53.4M | +1% |
| Nomura Asset Management International Inc. | 9.55M | 3.86% | $48.7M | +17% |
| Vanguard Portfolio Management LLC | 8.03M | 3.25% | $40.9M | +20% |
| Geode Capital Management, LLC | 6.40M | 2.59% | $32.7M | +7% |
| Jupiter Topco LLC | 5.30M | 2.15% | $27M | – |
| Two Sigma Investments, LP | 5.21M | 2.11% | $26.6M | +22% |
| Nuveen, LLC | 4.00M | 1.62% | $20.4M | -24% |
| Goldman Sachs Group Inc | 3.69M | 1.49% | $18.8M | +15% |
| AIGH Capital Management LLC | 3.20M | 1.30% | $16.3M | – |
| Morgan Stanley | 2.39M | 0.97% | $12.2M | +40% |
| AQR Capital Management LLC | 2.32M | 0.94% | $11.8M | -5% |
| Northern Trust Corp | 2.28M | 0.92% | $11.6M | +10% |
| Rock Springs Capital Management LP | 2.24M | 0.91% | $11.4M | -3% |
| Charles Schwab Investment Management Inc | 2.21M | 0.90% | $11.3M | +5% |
| Sixth Street Partners Management Company, L.P. | 2.21M | 0.90% | $11.3M | – |
| Bank of America Corp | 2.16M | 0.88% | $11M | -7% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ARDX insiders reported $1.9M of open-market purchases and $4.3M of sales. 48% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Susan Hohenleitner | CFO | Sale | 1,558 | $3.86 | $6K | Form 4 |
| Aug 21, 2026 | Joseph James Reilly | See Remarks | Sale | 1,110 | $3.86 | $4.3K | Form 4 |
| Aug 21, 2026 | Joseph James Reilly | See Remarks | Sale | 2,872 | $3.86 | $11.1K | Form 4 |
| Aug 21, 2026 | John E Bishop | See Remarks | Sale | 17,281 | $3.86 | $66.7K | Form 4 |
| Aug 21, 2026 | John E Bishop | See Remarks | Sale | 2,469 | $3.86 | $9.5K | Form 4 |
| Aug 21, 2026 | James Parker Brady | Chief Human Resources Of | Sale | 13,160 | $3.86 | $50.8K | Form 4 |
| Aug 21, 2026 | James Parker Brady | Chief Human Resources Of | Sale | 1,976 | $3.86 | $7.6K | Form 4 |
| Aug 21, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 2,598 | $3.86 | $10K | Form 4 |
| Aug 21, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 3,389 | $3.86 | $13.1K | Form 4 |
| Aug 21, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 2,575 | $3.86 | $9.9K | Form 4 |
| Aug 21, 2026 | Mike Kelliher | Chief Business Officer | Sale | 3,104 | $3.86 | $12K | Form 4 |
| Aug 21, 2026 | Mike Kelliher | Chief Business Officer | Sale | 2,002 | $3.86 | $7.7K | Form 4 |
| Aug 21, 2026 | Mike Kelliher | Chief Business Officer | Sale | 2,652 | $3.86 | $10.2K | Form 4 |
| Aug 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 3,486 | $3.86 | $13.5K | Form 4 |
| Aug 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 1,734 | $3.86 | $6.7K | Form 4 |
| Aug 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 2,430 | $3.86 | $9.4K | Form 4 |
| Aug 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 3,089 | $3.86 | $11.9K | Form 4 |
| Aug 21, 2026 | Michael Raab | CEO | Sale | 15,009 | $3.86 | $57.9K | Form 4 |
| Aug 21, 2026 | Michael Raab | CEO | Sale | 19,178 | $3.86 | $74K | Form 4 |
| Aug 21, 2026 | Michael Raab | CEO | Sale | 15,976 | $3.86 | $61.7K | Form 4 |
| Aug 21, 2026 | Michael Raab | CEO | Sale | 8,411 | $3.86 | $32.5K | Form 4 |
| Jul 15, 2026 | Michael Raab | CEO | Sale plan | 41,668 | $5.06 | $211K | Form 4 |
| Jun 18, 2026 | Laura A Williams | Chief Patient Officer | Sale plan | 81,898 | $5.99 | $491K | Form 4 |
| Jun 15, 2026 | Michael Raab | CEO | Sale plan | 41,666 | $5.67 | $236K | Form 4 |
| May 21, 2026 | Joseph James Reilly | See Remarks | Sale | 2,683 | $6.27 | $16.8K | Form 4 |
| May 21, 2026 | Joseph James Reilly | See Remarks | Sale | 1,036 | $6.27 | $6.5K | Form 4 |
| May 21, 2026 | Susan Hohenleitner | CFO | Sale | 1,455 | $6.27 | $9.1K | Form 4 |
| May 21, 2026 | John E Bishop | See Remarks | Sale | 2,306 | $6.27 | $14.5K | Form 4 |
| May 21, 2026 | James Parker Brady | Chief Human Resources Of | Sale | 1,846 | $6.27 | $11.6K | Form 4 |
| May 21, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 2,427 | $6.27 | $15.2K | Form 4 |
| May 21, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 3,166 | $6.27 | $19.9K | Form 4 |
| May 21, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 2,405 | $6.27 | $15.1K | Form 4 |
| May 21, 2026 | Mike Kelliher | Chief Business Officer | Sale | 2,900 | $6.27 | $18.2K | Form 4 |
| May 21, 2026 | Mike Kelliher | Chief Business Officer | Sale | 1,870 | $6.27 | $11.7K | Form 4 |
| May 21, 2026 | Mike Kelliher | Chief Business Officer | Sale | 2,478 | $6.27 | $15.5K | Form 4 |
| May 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 1,418 | $6.27 | $8.9K | Form 4 |
| May 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 1,911 | $6.27 | $12K | Form 4 |
| May 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 1,503 | $6.27 | $9.4K | Form 4 |
| May 21, 2026 | Laura A Williams | Chief Patient Officer | Sale | 2,157 | $6.27 | $13.5K | Form 4 |
| May 21, 2026 | Michael Raab | CEO | Sale | 14,028 | $6.27 | $88K | Form 4 |
| May 21, 2026 | Michael Raab | CEO | Sale | 17,926 | $6.27 | $112K | Form 4 |
| May 21, 2026 | Michael Raab | CEO | Sale | 7,861 | $6.27 | $49.3K | Form 4 |
| May 21, 2026 | Michael Raab | CEO | Sale | 14,933 | $6.27 | $93.6K | Form 4 |
| May 15, 2026 | Michael Raab | CEO | Sale plan | 41,666 | $6.28 | $262K | Form 4 |
| Apr 15, 2026 | Michael Raab | CEO | Sale plan | 41,668 | $6.29 | $262K | Form 4 |
| Mar 16, 2026 | Michael Raab | CEO | Sale plan | 41,666 | $5.84 | $243K | Form 4 |
| Feb 24, 2026 | Michael Raab | CEO | Sale | 41,666 | $6.26 | $261K | Form 4 |
| Feb 20, 2026 | David M Mott | Director | Purchase | 333,333 | $5.84 | $1.9M | Form 4 |
| Feb 20, 2026 | John E Bishop | See Remarks | Sale | 2,792 | $5.87 | $16.4K | Form 4 |
| Feb 20, 2026 | John E Bishop | See Remarks | Sale | 1 | $5.70 | $6 | Form 4 |
| Feb 20, 2026 | John E Bishop | See Remarks | Sale | 386 | $5.71 | $2.2K | Form 4 |
| Feb 20, 2026 | Joseph James Reilly | See Remarks | Sale | 602 | $5.71 | $3.4K | Form 4 |
| Feb 20, 2026 | Joseph James Reilly | See Remarks | Sale | 4,387 | $5.87 | $25.8K | Form 4 |
| Feb 20, 2026 | Joseph James Reilly | See Remarks | Sale | 2 | $5.70 | $11 | Form 4 |
| Feb 20, 2026 | Laura A Williams | See Remarks | Sale | 984 | $5.71 | $5.6K | Form 4 |
| Feb 20, 2026 | Laura A Williams | See Remarks | Sale | 7,192 | $5.87 | $42.2K | Form 4 |
| Feb 20, 2026 | Susan Hohenleitner | CFO | Sale | 1,786 | $5.87 | $10.5K | Form 4 |
| Feb 20, 2026 | Susan Hohenleitner | CFO | Sale | 247 | $5.71 | $1.4K | Form 4 |
| Feb 20, 2026 | James Parker Brady | Chief Human Resources Of | Sale | 2,234 | $5.87 | $13.1K | Form 4 |
| Feb 20, 2026 | James Parker Brady | Chief Human Resources Of | Sale | 309 | $5.71 | $1.8K | Form 4 |
| Feb 20, 2026 | Mike Kelliher | See Remarks | Sale | 8,434 | $5.87 | $49.5K | Form 4 |
| Feb 20, 2026 | Mike Kelliher | See Remarks | Sale | 1,159 | $5.71 | $6.6K | Form 4 |
| Feb 20, 2026 | Mike Kelliher | See Remarks | Sale | 2 | $5.71 | $11 | Form 4 |
| Feb 20, 2026 | Michael Raab | CEO | Sale | 40,401 | $5.87 | $237K | Form 4 |
| Feb 20, 2026 | Michael Raab | CEO | Sale | 5,576 | $5.71 | $31.8K | Form 4 |
| Feb 20, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 1,261 | $5.71 | $7.2K | Form 4 |
| Feb 20, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 1 | $5.71 | $6 | Form 4 |
| Feb 20, 2026 | Eric Duane Foster | Chief Commercial Officer | Sale | 9,176 | $5.87 | $53.9K | Form 4 |
| Jan 8, 2026 | Laura A Williams | Chief Patient Officer | Sale plan | 50,000 | $6.98 | $349K | Form 4 |
| Nov 21, 2025 | Elizabeth A Grammer | See Remarks | Sale | 5,995 | $5.54 | $33.2K | Form 4 |
| Nov 21, 2025 | Michael Raab | CEO | Sale | 46,887 | $5.54 | $260K | Form 4 |
| Nov 21, 2025 | Mike Kelliher | See Remarks | Sale | 5,560 | $5.54 | $30.8K | Form 4 |
| Nov 21, 2025 | Laura A Williams | Chief Patient Officer | Sale | 6,426 | $5.54 | $35.6K | Form 4 |
| Nov 21, 2025 | Eric Duane Foster | Chief Commercial Officer | Sale | 5,814 | $5.54 | $32.2K | Form 4 |
| Nov 21, 2025 | Joseph James Reilly | See Remarks | Sale | 11,086 | $5.54 | $61.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael Raab | President & CEO, Director | – | $2.6M | Aug 21, 2026 |
| David M Mott | Director | $1.9M | – | Feb 20, 2026 |
| Laura A Williams | Chief Patient Officer | – | $1M | Aug 21, 2026 |
| Eric Duane Foster | Chief Commercial Officer | – | $176K | Aug 21, 2026 |
| Mike Kelliher | See Remarks | – | $162K | Aug 21, 2026 |
| Joseph James Reilly | See Remarks | – | $129K | Aug 21, 2026 |
| John E Bishop | See Remarks | – | $109K | Aug 21, 2026 |
| James Parker Brady | Chief Human Resources Officer | – | $84.9K | Aug 21, 2026 |
| Elizabeth A Grammer | See Remarks | – | $33.2K | Nov 21, 2025 |
| Susan Hohenleitner | Chief Financial Officer | – | $27K | Aug 21, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ARDX short interest
High short interest. 11.6% of ARDX shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 29.21M ARDX shares were sold short, 11.6% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 3.88M shares, buying them all back would take about 7.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 29.21M | 11.62% | -3% | 3.88M | 7.5 |
| Oct 15, 2026 | 30.24M | 12.13% | +9% | 4.67M | 6.5 |
| Sep 30, 2026 | 27.68M | 11.11% | +8% | 4.19M | 6.6 |
| Sep 15, 2026 | 25.60M | 10.27% | +13% | 4.04M | 6.3 |
| Aug 31, 2026 | 22.72M | 9.12% | +1% | 3.70M | 6.1 |
| Aug 14, 2026 | 22.43M | 9.00% | -15% | 6.77M | 3.3 |
| Jul 31, 2026 | 26.24M | 10.53% | No change | 2.38M | 11.0 |
| Jul 15, 2026 | 26.25M | 10.63% | +3% | 3.26M | 8.1 |
| Jun 30, 2026 | 25.37M | 10.27% | -6% | 6.28M | 4.0 |
| Jun 15, 2026 | 26.94M | 10.91% | +9% | 3.14M | 8.6 |
| May 29, 2026 | 24.78M | 10.03% | +4% | 2.56M | 9.7 |
| May 15, 2026 | 23.86M | 9.66% | +1% | 5.25M | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ardelyx company events
Ardelyx filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 17, 2026AnnouncementEric Foster notified Ardelyx, Inc. of his decision to resign as Chief Commercial Officer of the Company, effective August 28, 2026. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 2, 2026DebtTook on new debt. Filing
- Jun 17, 2026LeadershipThe Board of Directors of Ardelyx, Inc. approved the second amendment to the Company’s Amended and Restated 2014 Equity Incentive Award Plan. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementThe information set forth in Item 2.02 is incorporated into this Item 8.01 by reference. Filing
- Dec 17, 2025LeadershipElizabeth Grammer informed Ardelyx, Inc. of her resignation as the Company’s Chief Legal and Administrative Officer, effective December 31, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ardelyx financials
Famous investors that hold ARDX
3 of the 50 well-known investors we track reported holding ARDX in their latest 13F filing. The largest position is Israel Englander's, worth $46M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 13.46M | $46M | 0.0% | -3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.39M | $4.7M | 0.0% | +35% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 119,067 | $407K | 0.0% | -87% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Ardelyx, Inc. (ARDX) stock
Who owns the most ARDX stock?
The largest reported owner of Ardelyx, Inc. (ARDX) is BlackRock, Inc., with 9.5% of the company. In total, 248 funds and institutions reported holding ARDX at the end of Q2 2026, together about 73% of the shares. See the largest owners.
Are ARDX insiders buying or selling?
In the last 12 months, ARDX insiders reported 1 open-market purchase worth $1.9M and 74 sales worth $4.3M. The latest trade was on Aug 21, 2026. See every trade.
What is the short interest in ARDX?
As of Oct 30, 2026, 29.21M ARDX shares were sold short, 11.6% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 3.88M shares, buying them all back would take about 7.5 trading days (days to cover). See the history.
Which famous investors hold ARDX?
3 of the 50 well-known investors we track reported ARDX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $46M. See all holders.
Executive pay
Ardelyx's chief executive was paid a total of $7.8M for the year ended Dec 31, 2025, down 19% from $9.6M the year before. In the last 12 months, Ardelyx's executives and directors bought $1.9M of stock on the open market and sold $4.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.